Advances in Cancer Immunotherapyâ„¢ 2014 Regional Programs

CME-Certified Regional Program Locations and Dates

Planning Committee

Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists

 

Program Purpose

Specifically designed for clinical oncologists and the entire medical team involved in treating cancer patients with immunotherapy, these introductory, CME-certified programs will provide an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discuss emerging drugs and concepts in the cancer immunotherapy field.

Presented by leading authorities in tumor immunology and cancer immunotherapy, these programs will facilitate understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes. 

Attendees can also take advantage of the opportunity for professional networking that will promote collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.

Intended Audience

The target audience for these programs includes clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.

Educational Objectives

Upon completion of this program, the participants will be able to:

  • Interpret the key principles of tumor immunology and immunotherapy
  • Analyze recent research and clinical applications of cytokines, cancer vaccines, T cell checkpoint inhibitors, adoptive immunotherapy and biomarkers
  • Participate in scientific exchange with local colleagues, potential collaborators, and subject matter experts on research and clinical application of cancer immunotherapy
  • Implement cancer immunotherapy treatments into clinical practice more effectively through a sound understanding of how they work, the clinical management of patients, and the potential to improve patient outcomes with tumor immunotherapy

Continuing Medical Education

The Advances in Cancer Immunotherapy™ programs have been approved for continuing medical education credits by Clinical Immunology Society (CIS) and Society for Immunotherapy of Cancer (SITC)

For full accreditation information, please click on the regional ACI™ program links above.

This series of programs have been made possible in part by educational grants from:

  • AstraZeneca
  • Bristol-Myers Squibb
  • Dendreon
  • Merck
  • Prometheus

To view all of SITC’s supporters, please, click here.